Antani, Abraham B.
HRN: 21-93-42 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/24/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
09/24/2022
09/30/2022
IV
150mg
Q8
Amoebiasis
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes